|
Abdominal Migraine
|
0.300 |
Biomarker
|
disease |
CTD_human |
Clinical features in a family with an R460H mutation in transforming growth factor beta receptor 2 gene.
|
16885183 |
2006 |
|
Abdominal Pain
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality iris morphology
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Abnormality of the sternum
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of the voice
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Acquired Camptodactyly
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Acute Confusional Migraine
|
0.300 |
Biomarker
|
disease |
CTD_human |
Clinical features in a family with an R460H mutation in transforming growth factor beta receptor 2 gene.
|
16885183 |
2006 |
|
Adams-Oliver syndrome 1
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Molecular testing of the TGFBR1 and TGFBR2 genes, involved in LDS, resulted negative, but analysis of SMAD3 disclosed the novel heterozygous loss-of-function mutation c.1170_1179del (p.Ser391AlafsX7) in exon 9 in all affected family members, confirming the diagnosis of AOS.
|
23554019 |
2013 |
|
Adenocarcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical staining with TGFBR2 antibody revealed statistically significant or near significant differences in the reduced expression in LCC (80% of cases) versus AdC (42.1% of cases, P=0.0288) and SqC (47.1% of cases, P=0.0589), or LCC versus non-LCC (45% of cases, P=0.02).
|
17566598 |
2007 |
|
Adenocarcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Tgfbr2 was methylated and markedly down-regulated in three of seven 3,2'-dimethyl-4-aminobiphenyl-induced invasive adenocarcinomas in the dorsolateral lobe of the rat prostate.
|
18381416 |
2008 |
|
Adenocarcinoma
|
0.070 |
GeneticVariation
|
group |
BEFREE |
We investigated the association between RII mutations and various clinicopathological variables and genetic alterations in a large series of sporadic adenocarcinomas arising in the proximal colon.
|
9664904 |
1998 |
|
Adenocarcinoma
|
0.070 |
Biomarker
|
group |
BEFREE |
In conclusion, combined inactivation of both Apc and Tgfbr2 in the colon epithelium of a CRC mouse model promoted development of adenocarcinoma in the proximal colon.
|
27835699 |
2016 |
|
Adenocarcinoma
|
0.070 |
AlteredExpression
|
group |
LHGDN |
Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness.
|
15976377 |
2005 |
|
Adenocarcinoma
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Six additional RII mutations were all found in highly progressed adenomas that contained regions of frankly invasive adenocarcinoma.
|
9679977 |
1998 |
|
Adenocarcinoma
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Homozygous or heterozygous TGFβRII deletion in mouse airway epithelia increases the size and number of Kras(G12D)-initiated adenocarcinoma and SCC.
|
22399565 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
We previously showed that targeting Kras(G12D) activation and transforming growth factor β receptor type II (TGFβRII) deletion to airway basal cells via a keratin promoter induced formation of both lung AdC and SCC.
|
23625632 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
This study was designed to determine whether reduced expression of TGFβ type II receptor (TGFβRII) promotes lung adenocarcinoma and SCC carcinogenesis.
|
22399565 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.050 |
Biomarker
|
disease |
BEFREE |
Clinical investigations have suggested that repression of the TGF-β type II receptor (TβRII) may be an important step in progression of lung adenocarcinoma from an indolent in situ state to a frank invasive carcinoma.
|
21911454 |
2011 |
|
Adenocarcinoma of lung (disorder)
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
NCI-H23, a human non-small-cell lung adenocarcinoma cell line which has a frameshift mutation in, and reduced expression of, the TGF-beta type-II receptor (TGF-beta RII), exhibits resistance to growth inhibition by TGF-beta(1) in vitro.
|
12399125 |
2002 |
|
Adenocarcinoma of lung (disorder)
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to test whether TGF-β1 C509T and TGF-β receptor II (TGFBR2) G-875A polymorphisms were associated with lung adenocarcinoma in nonsmoking females.
|
25928368 |
2015 |
|
Adenocarcinoma of pancreas
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Adenocarcinoma of pancreas
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
In this study, we determined the incidence of microsatellite instability (MIN) in pancreatic adenocarcinoma and determined whether MIN might target, for mutations, the simple nucleotide repeats of the transforming growth factor beta type II receptor (TGFBR2) gene.
|
9598801 |
1998 |
|
Adenocarcinoma of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two triplets (MIR22HG_hsa-mir-21_TGFBR2 and MIR22HG_hsa-mir-21_BCL2) were finally identified; not only were they significantly associated with PRAD survival but they also had the highest average degree in the identified subnetwork.
|
31579415 |
2019 |
|
Adenoma
|
0.020 |
GeneticVariation
|
group |
BEFREE |
These RII mutations were detected in both the advanced adenomas and their adjacent regions of carcinoma.
|
9679977 |
1998 |
|
Adenoma
|
0.020 |
Biomarker
|
group |
BEFREE |
Two cases showed a missense mutation at codon 191 or loss of heterozygosity in TGF-beta RII in both the adenoma and cancer.
|
9566701 |
1998 |